Donate For Public and Patients Store Search

S003 - New Emerging Therapies

Friday, March 1; 9:00 AM - 12:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Identify new treatments and therapies that are either available now or will be available in the near future to treat psoriasis, acne, rosacea, hair loss, atopic dermatitis, nonmelanoma skin cancer, as well as infections of the skin.
  • Evaluate present and future therapies for prevention and treatment of scars.
  • Develop treatment algorithms to expand our options for minimally invasive cosmetic dermatology.

Description

This session is designed to present new emerging therapies that are available either now or in the near future for both common dermatologic conditions, including psoriasis, atopic dermatitis, acne, rosacea, infections of the skin and nonmelanoma skin cancer, as well as scar therapy and minimally invasive cosmetic procedures.

Disclosures

  • Ablon, Glynis R., MD: Galderma Laboratories, L.P. – A(H);
  • Berman, Brian, MD, PhD: Aclaris Therapeutics, Inc. – A(H), C(H); Actavis – I(Grants/Research Funding); AiViva BioPharma, Inc. – C(H); Allergan, Inc. – I(Grants/Research Funding); Allos – A(H); Almirall – A(H); Amira Pharmaceuticals – C(H); Anacor Pharmaceuticals, Inc. – A(H), I(Grants/Research Funding); Bayer Pharmaceuticals – SP(H); Berg Pharma, LLC – A(ST), C(H); Biofrontera AG – C(H), I(Grants/Research Funding); BirchBioMed – A(H); C & H Scientific, LLC – A(H); Capstone Therapeutics Corp. – C(H); Celgene – I(Grants/Research Funding); Celumigen Pharmaceuticals, Inc. – B(SO), C(H), C(SO); Centocor Ortho Biotech Inc. – C(H), SP(H); CHS Pharma – A(ST); Clark Pharmaceuticals, LLC – C(H); Crescita Therapeutics Inc. – C(H); Cutanea Life Sciences – A(H); Dermira – A(H); Doak – A(H); Dr. Tattoff – A(H), A(SO); DUSA Pharmaceuticals, Inc – A(H); DUSA Pharmaceuticals, Inc. – C(H), I(Grants/Research Funding); Encore Dermatology, Inc. – I(Grants/Research Funding); Excaliard Pharmaceuticals, Inc. – C(H); Exeltis – C(H), I(Grants/Research Funding); Ferndale Laboratories, Inc. – C(H); Foamix – A(H); Galderma Laboratories, L.P. – A(H), I(Grants/Research Funding), SP(H); GlaxoSmithKline – C(H); Graceway Pharmaceuticals, LLC – SP(H); Halscion – A(H); Incyte Corporation – I(Grants/Research Funding); Innovaderm Research Inc. – I(Grants/Research Funding); IntraDerm Pharmaceuticals – A(H), C(H); Klara/Goderma, Inc. – C(SO); Leo Pharma A/S – I(Grants/Research Funding); LEO Pharma, US – A(H), SP(H); Liquidia Technologies, Inc. – C(H); Medicis Pharmaceutical Corporation – A(H), SP(H); Medimetriks Pharmaceuticals, Inc. – C(H); MediWound – C(H); Menlo Therapeutics – A(H), I(Grants/Research Funding); Merz Pharmaceuticals, LLC – A(H), Speaker/Faculty Education(H); miRagen Therapeutics, Inc. – C(H), I(Grants/Research Funding); Novan – C(H); Novartis Pharmaceuticals Corp. – SP(H); Oculus innovative Sciences, Inc. – C(SO); Onset Therapeutics – A(H), SP(H); Peplin Inc. – A(H), C(H); Pharmaderm – A(H); Pulse Biosciences – C(H); Realm Therapeutics – C(H); RXi Pharmaceuticals Corporation – I(NC); sanofi-aventis – A(H), SP(H); Seattle Genetics – A(H); Sensus Healthcare – A(H), SP(H); Sirnaomics, Inc. – C(H); SiSaf, Ltd. – C(H); Smith & Nephew – A(H); Sol-Gel Technologies – C(H); Sonoma Pharmaceuticals – C(SO); Stiefel a GSK company – A(H), SP(H); Tigercat Pharma, Inc – I(Grants/Research Funding); TopMD – A(ST), C(H); Valeant Pharmaceuticals International – SP(H); Verrica Pharmaceuticals Inc – C(H);
  • Berson, Diane S., MD: Aclaris Therapeutics Inc. – C(H); Allergan, Inc – C(H); Almirall – A(H); Ferndale Laboratories, Inc. – C(H); Galderma Laboratories, L.P. – A(H); La Roche-Posay Laboratoire Pharmaceutique – A(H); Ortho Dermatologics – A(H); Procter & Gamble Company – C(H); Revance Therapeutics, Inc. – A(H); Sienna Biopharmaceuticals – A(H); Skinfix, Inc. – A(H); Taro Pharm – A(H); TopMD – C(H);
  • Cohen, David Eric, MD: Bickel Biotechnology – B(SO); Celgene – A(H); Cutanea Life Sciences – A(H); Dermira – B(Fees), B(ST); Facilitation of International Dermatology Education – C(H); Ferndale Laboratories, Inc. – C(H); Ferrer – A(H); Kadmon Corporation, LLC – B(Fees); Medimetriks Pharmaceuticals, Inc. – C(H), C(SO); Novartis – C(H);
  • Goldberg, David J., MD, JD: Aerolase – I(Grants/Research Funding); Allergan, Inc. – I(Grants/Research Funding); BTL Industries – I(Grants/Research Funding); Cutera, Inc. – I(Grants/Research Funding); Galderma Laboratories, L.P. – I(Grants/Research Funding); Guidepoint Global, LLC – C(Fees); Lumenis – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Sensus Healthcare – C(Fees); Sienna Biopharmaceuticals – I(Grants/Research Funding); Syneron, Inc. – I(Grants/Research Funding);
  • Kircik, Leon H., MD: 3M Pharmaceuticals – I(Grants/Research Funding), SP(H); Abbott Laboratories – SP(H); Ablynx – I(Grants/Research Funding); Acambis – I(Grants/Research Funding); Allergan, Inc – A(H), C(H), I(H), SP(H); Almirall – C(H); Amgen – C(H), I(Grants/Research Funding), SP(H); AnaptysBio – I(Grants/Research Funding); Aqua – A(H); Astellas Pharma US, Inc – I(Grants/Research Funding), SP(H); Asubio Pharmaceuticals, Inc. – I(Grants/Research Funding); Bayer Consumer Healthcare Pharmaceuticals – I(Grants/Research Funding); Beiersdorf, Inc. – C(H), I(Grants/Research Funding); Biogen – A(H); Biolife – I(Grants/Research Funding); Biopelle, Inc. – I(Grants/Research Funding); Breckinridge Pharma – I(Grants/Research Funding); Cassiopea SpA – C(H); Centocor Ortho Biotech Inc. – I(Grants/Research Funding); ColBar LifeScience Ltd. – A(H), C(H); CollaGenex Pharmaceuticals, Inc. – C(H), I(Grants/Research Funding), SP(H); Connetics Corporation – A(H), C(H), I(Grants/Research Funding); Coria Laboratories – I(Grants/Research Funding); Dermik Laboratories, a business of sanofi-aventis U.S. LLC – SP(H); Dow Pharmaceutical Sciences, Inc. – I(Grants/Research Funding); DUSA Pharmaceuticals, Inc. – I(Grants/Research Funding); Embil Pharmaceuticals, Co., Ltd – SP(H); EOS – A(H); Ferndale Laboratories, Inc. – A(H), I(Grants/Research Funding); Galderma Laboratories, L.P. – A(H), C(H), I(Grants/Research Funding), SP(H); Genentech, Inc. – A(H), C(H), I(Grants/Research Funding), SP(H); GlaxoSmithKline – I(Grants/Research Funding); Healthpoint – I(Grants/Research Funding); Intendis, Inc. – A(H), C(H), I(Grants/Research Funding); Isdin – A(H); Johnson & Johnson Consumer Products Company – A(H), C(H), I(Grants/Research Funding), SH(ST), SP(H); Laboratory Skin Care, Inc. – C(H); Leo Pharma Inc – C(H), I(Grants/Research Funding), SP(H); Medical International Technologies – C(H); Medicis Pharmaceutical Corporation – I(Grants/Research Funding); Merck & Co., Inc – C(H); Merck Serono – SP(H); Merz Pharmaceuticals, LLC – C(H); NanoBio Corporation – A(H), I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – C(H), I(Grants/Research Funding); Nucryst – I(Grants/Research Funding); Obagi Medical Products – I(Grants/Research Funding); Onset Dermatologics – I(Grants/Research Funding), SP(H); Othro Dermatologics – A(H), C(H), I(Grants/Research Funding), SP(H); Pfizer Inc. – I(Grants/Research Funding); Pharmaderm – I(Grants/Research Funding), SP(H); Promius Pharma, LLC – A(H), C(H), I(Grants/Research Funding); PuraCap Pharmaceutical – C(H); QLT Inc. – I(H); SkinMedica, Inc. – A(H), C(H), I(Grants/Research Funding), SP(H); Stiefel a GSK company – A(H), C(H), I(Grants/Research Funding), SP(H); Sun Pharmaceutical Industries Ltd. – A(H), SP(H); Taro Pharm – C(H), I(Grants/Research Funding); TolerRx – I(Grants/Research Funding); Triax Pharmaceuticals, LLC – C(H), I(Grants/Research Funding), SP(H); Valeant Pharmaceuticals International – A(H), C(H), I(Grants/Research Funding), SP(H); Warner Chilcott – A(H), I(Grants/Research Funding), SP(H); Xenoport, Inc. – I(Grants/Research Funding); Zalicus – I(Grants/Research Funding);
  • Nestor, Mark S., MD, PhD: Aclaris Therapeutics Inc. – I(Grants/Research Funding); Aclaris Therapeutics, Inc. – A(H); Actavis – I(Grants/Research Funding); Aerolase – A(H), C(H), I(Grants/Research Funding), SP(H); Afecta Pharmaceuticals – C(H), I(Grants/Research Funding); Allergan, Inc – I(Grants/Research Funding); Almirall – A(H), C(H); Biofrontera AG – A(H), I(Grants/Research Funding); BirchBioMed – A(H), I(Grants/Research Funding); Brickell Biotech, Inc. – I(Grants/Research Funding); Cara Therapeutics – I(Grants/Research Funding); Castle Biosciences, Inc – A(H); Celgene Corporation – I(Grants/Research Funding); Croma-Pharma GmbH Austria – C(H), I(Grants/Research Funding); Demira – I(Grants/Research Funding); Encore Dermatology, Inc. – I(Grants/Research Funding); Essence Novel – A(H); Evolus, Inc. – A(H), C(H), I(Grants/Research Funding); Ferndale Laboratories, Inc. – A(H), C(H), I(Grants/Research Funding); Gage Development Company, LLC – I(Grants/Research Funding); Galderma Laboratories, LP – A(H), I(Grants/Research Funding); I.F.C., S.A. – I(Grants/Research Funding), SP(H); Incyte Corporation – I(Grants/Research Funding); IntraDerm Pharmaceuticals – A(H), I(Grants/Research Funding), SP(H); Ipsen – C(H); ISDIN – A(H); Johnson & Johnson Pharmaceutical Research & Development – I(Grants/Research Funding); Johnson and Johnson – A(H), C(H); Leo Pharma Inc – I(Grants/Research Funding); Leo Pharma Inc. – A(H); MC2 Therapeutics – I(Grants/Research Funding); Menlo Therapeutics – I(Grants/Research Funding); miRagen Therapeutics, Inc. – I(Grants/Research Funding); Pulse Biosciences – C(H), I(Grants/Research Funding); Ralexar Therapeutics, Inc – I(Grants/Research Funding); Rohrer Aesthetics – C(H), SP(H); Sensus Healthcare – A(H), C(H), Speaker/Faculty Education(H); Sinclair Pharma – A(H), C(H), I(Grants/Research Funding); Sirnaomics, Inc. – I(Grants/Research Funding); SiSaf, Ltd. – SP(H); Stratapharma – A(H); Strathspey Crown – SH(NC); Therapeutics Inc – I(Grants/Research Funding); ThermiAesthetics – A(H), C(H), SP(H); Vanda Pharmaceuticals Inc. – I(Grants/Research Funding);
  • Rosen, Theodore, MD: Foamix – A(H); Medimetriks Pharmaceuticals, Inc. – C(H); Menlo Therapeutics – A(H); Valeant Pharmaceuticals International – C(H);
Schedule
Friday, March 1
9:00 AM
Dr. Nestor / Introduction
9:04 AM
Dr. Kircik / New and Emerging Therapies for Psoriasis with Q&A
9:26 AM
Dr. Nestor / New and Emerging Therapies in Aesthetic Dermatology with Q&A
9:48 AM
Dr. Berson / A New Cosmeceutical for Estrogen Deficient Skin with Q&A
10:10 AM
Dr. Ablon / New and Emerging Therapies for Hair loss with Q&A
10:32 AM
Dr. Cohen / New and Emerging Therapies for Atopic Dermatitis with Q&A
10:54 AM
Dr. Goldberg / New and Emerging Therapies for NMSC with Q&A
11:16 AM
Dr. Berman / New and Emerging Therapies for Scars with Q&A
11:38 AM
Dr. Rosen / New and Emerging Therapies in Infections of the Skin with Q&A
Event Details
  • Date
    Friday, March 1
  • Time
    9:00 AM - 12:00 PM
  • Location
    Ballroom C
  • CME Credits
    3.00
  • Type
Directors/Co-Directors
  • Mark S. Nestor, MD, PhD, FAAD
Speakers
  • Brian Berman, MD, PhD, FAAD
  • David Eric Cohen, MD, FAAD
  • David J. Goldberg, MD, JD, FAAD - Handout
  • Diane S. Berson, MD, FAAD - Handout
  • Glynis R. Ablon, MD, FAAD
  • Leon H. Kircik, MD, FAAD
  • Theodore Rosen, MD, FAAD